IDEXX Laboratories, Inc.
627.66-6.70 (-1.06%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · IDXX · USD
Key Stats
Market Cap
50.22BP/E (TTM)
52.09Basic EPS (TTM)
12.05Dividend Yield
0%Recent Filings
8-K
IDEXX adds tech-savvy director
IDEXX Laboratories elected Karen Peacock as an independent Class I director effective October 6, 2025, expanding the board from ten to eleven members. Peacock, former CEO of Intercom and ex-SVP at Intuit, brings deep B2B SaaS and AI expertise to bolster IDEXX's innovation in pet diagnostics and software. She joins the Compensation and Talent and Finance Committees. Her skills sharpen board oversight amid evolving tech demands.
8-K
IDEXX Q2 revenue up 11%
IDEXX Laboratories reported Q2 2025 revenue of $1,109 million, up 11% as reported and 9% organic, fueled by 9% growth in CAG Diagnostics recurring revenue and record placements of nearly 2,400 IDEXX inVue Dx instruments. EPS hit $3.63, surging 49% as reported and 17% on a comparable basis, boosted by prior-year litigation comparisons and tax benefits. The company raised full-year revenue guidance to $4,205-$4,280 million and EPS to $12.40-$12.76, signaling sustained innovation momentum. Yet litigation resolutions linger as a resolved risk.
10-Q
Q2 FY2025 results
IDEXX Laboratories posted solid Q2 results, with revenue climbing 10.6% year-over-year to $1.11B, fueled by 9.7% organic growth in the core CAG segment where VetLab consumables surged 15.3% on higher volumes and prices. Gross margins expanded 90 basis points to 62.6%, thanks to productivity gains offsetting inflation, while operating income jumped 41.4% to $373M after shedding a one-time litigation hit from last year. Diluted EPS rose 48.8% to $3.63, aligning with 80,994 weighted shares. Cash from operations held steady at $424M year-to-date, but heavy stock buybacks totaling $739M pushed net cash down; debt sits at $1.1B with $669M revolver room and no covenant issues. Free cash flow came in at $360M (derived). Yet competition in diagnostics could squeeze margins if pricing softens.
8-K
IDEXX adds finance veteran to board
IDEXX Laboratories elected Joseph L. (Jay) Hooley, former CEO of State Street Corporation, as an independent Class III director effective July 10, 2025, expanding the board to ten members and appointing him to the Audit and Governance committees. Hooley's financial leadership and governance expertise from steering State Street's global expansion will sharpen IDEXX's strategic oversight in pet healthcare innovation. Board now boasts nine independents. Yet risks lurk in forward-looking assumptions.
8-K
Governance overhaul approved
IDEXX Laboratories eliminated its Series A Preferred Stock and amended its Certificate of Incorporation on May 7, 2025, scrapping supermajority voting requirements and adding officer exculpation under Delaware law—both approved overwhelmingly by shareholders at the annual meeting. The board simultaneously updated bylaws to streamline director nominations, set Delaware courts as the exclusive forum for corporate disputes, and ease special meeting calls. These tweaks boost governance flexibility. Yet risks linger in forum selection disputes.
IPO
Website
Employees
Sector
Industry
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
CODX
Co-Diagnostics, Inc.
0.49-0.08
CRL
Charles River Laboratories Inte
180.15-7.78
DGX
Quest Diagnostics Incorporated
174.78-3.50
DHR
Danaher Corporation
214.01-2.89
IDXG
Interpace Biosciences, Inc.
1.10-0.04
ILMN
Illumina, Inc.
95.03-2.77
LH
Labcorp Holdings Inc.
248.14-11.55
NEOG
Neogen Corporation
6.23+0.07
WAT
Waters Corporation
343.47-2.48